

IN THE CLAIMS:

Cancel claims 5 and 7.

Amend claims 1, 3, 4, 6, 15 and 16 as follows, the amendments being shown by brackets and underlining in an Appendix hereto:

Sub 1
C1
1. (Twice Amended) Transdermal therapeutic system comprising a backing layer, at least one nicotine-containing layer or zone, and an additive comprising spearmint oil or at least one monoterpene ketone contained in spearmint oil, wherein the content of at least one monoterpene ketone in the nicotine-containing layer or zone is 0.1 to 5.0%-wt of the weight of the layer or zone.

C2
3. (Twice Amended) Transdermal therapeutic system according to claim 2, wherein the monoterpene ketone is a pure enantiomer thereof or a mixture of enantiomers thereof.

C3
4. (Twice Amended) Transdermal therapeutic system according to claim 1, wherein the additive comprises spearmint oil.

Sub 2
C3
6. (Twice Amended) Process for masking an unpleasant smell, caused by the presence of nicotine, comprising adding to a nicotine-containing layer or zone of a nicotine-containing transdermal therapeutic system, 0.1 to 5.0%-wt, based on the weight of the layer or zone, of at least one odor-improving

C3
cond'd

substance, said substance being spearmint oil or at least one monoterpene ketone contained in spearmint oil.

sub 03
C4

15. (Amended) Transdermal therapeutic system according to claim 5, wherein the content of the at least one monoterpene ketone in the nicotine-containing layer or zone is 0.5- 2% wt of the weight of the layer or zone.

16. (Amended) Process according to claim 6, wherein the at least one monoterpene ketone is added to the nicotine - containing layer or zone in a quantity constituting 0.5-2% wt of said layer or zone.
